E-viri
PDF
Recenzirano
Odprti dostop
-
Al-Hendy, Ayman; Lukes, Andrea S; Poindexter, Alfred N; Venturella, Roberta; Villarroel, Claudio; Critchley, Hilary O.D; Li, Yulan; McKain, Laura; Arjona Ferreira, Juan C; Langenberg, Andria G.M; Wagman, Rachel B; Stewart, Elizabeth A
The New England journal of medicine, 02/2021, Letnik: 384, Številka: 7Journal Article
In two international, randomized, double-blind, 24-week, phase 3 trials involving women with uterine fibroid–associated heavy menstrual bleeding, therapy with relugolix (an oral gonadotropin-releasing hormone receptor antagonist), combined with estradiol and norethindrone acetate, led to a significant reduction in menstrual bleeding while preserving bone mineral density.
